Prosthetic joint infection: Diagnosis and management

Expert Review of Anti-Infective Therapy

Volumn 9, Issue 9, 2011, Pages 787-802

  Cobo, Javier ^a   Del Pozo, Jose Luis ^b  

^a HOSPITAL RAMÓN Y CAJAL   (Spain)

^b UNIVERSITY CLINIC OF NAVARRA   (Spain)

Author keywords

chronic suppressive therapy; prosthetic arthroplasty infection; prosthetic joint infection; rifampin

Indexed keywords

ANTIBIOTIC AGENT; BONE CEMENT; CIPROFLOXACIN; COTRIMOXAZOLE; DAPTOMYCIN; FUSIDIC ACID; LEVOFLOXACIN; LINEZOLID; MINOCYCLINE; RIFAMPICIN;

BLOOD CELL COUNT; BLOOD TOXICITY; CLINICAL FEATURE; DEBRIDEMENT; DEVICE REMOVAL; DRUG MEGADOSE; HEALTH CARE MANAGEMENT; HIP ARTHROPLASTY; HISTOPATHOLOGY; HUMAN; JOINT ASPIRATION; JOINT PROSTHESIS; JOINT RADIOGRAPHY; KNEE ARTHROPLASTY; LABORATORY TEST; MICROBIOLOGICAL EXAMINATION; MORTALITY; NEUROTOXICITY; NONHUMAN; PATHOGENESIS; PROSTHESIS INFECTION; PROSTHESIS LOOSENING; PROSTHETIC JOINT INFECTION; REVIEW; RISK FACTOR; TREATMENT DURATION; UNSPECIFIED SIDE EFFECT;

ANTI-INFECTIVE AGENTS; ARTHRITIS; BIOFILMS; CHRONIC DISEASE; DRUG ADMINISTRATION ROUTES; DRUG ADMINISTRATION SCHEDULE; GRAM-NEGATIVE BACTERIA; GRAM-POSITIVE BACTERIA; HUMANS; INDIVIDUALIZED MEDICINE; JOINT PROSTHESIS; MAGNETIC RESONANCE IMAGING; MICROBIAL SENSITIVITY TESTS; PAIN; PAIN MANAGEMENT; PROSTHESIS-RELATED INFECTIONS; SONICATION; TOMOGRAPHY, X-RAY COMPUTED;

EID: 80052776716     PISSN: 14787210     EISSN: 17448336     Source Type: Journal    
DOI: 10.1586/eri.11.95     Document Type: Review

References (120)

1. Love C, Marwin SE, Palestro CJ. Nuclear medicine and the infected joint replacement. Semin. Nucl. Med. 39, 66-78 (2009).
2. Kurtz S, Ong K, Lau E et al. Projections of primary and revision hip and knee arthroplasty in the United States from 2005 to 2030 J. Bone Joint Surg. Am. 89, 780-785 (2007). (Pubitemid 46564282)
3. Zimmerli W, Trampuz A, Ochsner PE. Prosthetic-joint infections. N. Engl. J. Med. 351, 1645-1654 (2004).
4. Berbari EF, Hanssen AD, Duffy MC et al. Risk factors for prosthetic joint infection, case-control study. Clin. Infect. Dis. 27, 1247-1254 (1998). (Pubitemid 29242479)
5. Bongartz T, Halligan CS, Osmon DR et al. Incidence and risk factors of prosthetic joint infection after total hip or knee replacement in patients with rheumatoid arthritis. Arthritis Rheum. 59, 1713-1720 (2008).
6. Murdoch DR, Roberts SA, Fowler JV Jr et al. Infection of orthopedic prostheses after Staphylococcus aureus bacteremia. Clin. Infect. Dis. 32, 647-649 (2001). (Pubitemid 32565009)
7. Asensio A, Ramos A, Munez E et al. Preoperative low molecular weight heparin as venous thromboembolism prophylaxis in patients at risk for prosthetic infection after knee arthroplasty. Infect. Cont. Hosp. Epidemiol. 26, 903-909 (2005). (Pubitemid 43088871)
8. Fisman DN, Reilly DT, Karchmer AW, Goldie SJ. Clinical effectiveness and cost-effectiveness of 2 management strategies for infected total hip arthroplasty in the elderly. Clin. Infect. Dis. 32, 419-430 (2001). (Pubitemid 32173628)
9. Lentino JR. Prosthetic joint infections, bane of orthopedists, challenge for infectious disease specialists. Clin. Infect. Dis. 36, 1157-1161 (2003). (Pubitemid 36549638)
10. Trampuz A, Hanssen AD, Osmon DR et al. Synovial fluid leukocyte count and differential for the diagnosis of prosthetic knee infection. Am. J. Med. 117, 556-562 (2004). (Pubitemid 39304205)
11. Weil Y, Mattan Y, Liebergall M, Rahav G. Brucella prosthetic joint infection, a report of 3 cases and a review of the literature. Clin. Infect. Dis. 36, e81-e86 (2003).
12. Phelan DM, Osmon DR, Keating MR, Hanssen AD. Delayed reimplantation arthroplasty for candidal prosthetic joint infection, a report of 4 cases and review of the literature. Clin. Infect. Dis. 34, 930-938 (2002). (Pubitemid 34229761)
13. Eid AJ, Berbari EF, Sia IG et al. Prosthetic joint infection due to rapidly growing mycobacteria, report of 8 cases and review of the literature. Clin. Infect. Dis. 45, 687-694 (2007). (Pubitemid 47378881)
14. Marculescu CE, Berbari EF, Cockerill FR 3rd, Osmon DR. Fungi, mycobacteria, zoonotic and other organisms in prosthetic joint infection. Clin. Orthop. Relat. Res. 451, 64-72 (2006). (Pubitemid 44515007)
15. Zaman R, Abbas M, Burd E. Late prosthetic hip joint infection with Actinomyces israelii in an intravenous drug user, case report and literature review. J. Clin. Microbiol. 40, 4391-4392 (2002). (Pubitemid 35285854)
16. Berbari EF, Marculescu C, Sia I et al. Culture-negative prosthetic joint infection. Clin. Infect. Dis. 45, 1113-1119 (2007). (Pubitemid 47580309)
17. Darouiche RO. Device-Associated infections, a macroproblem that starts with microadherence. Clin. Infect. Dis. 33, 1567-1572 (2001). (Pubitemid 34246153)
18. Zimmerli W, Waldvogel FA, Vaudaux P, Nydegger UE. Pathogenesis of foreign body infection, description and characteristics of an animal model. J. Infect. Dis. 146, 487-497 (1982). (Pubitemid 12004448)
19. Ceri H, Olson ME, Stremick C et al. The Calgary biofilm device, new technology for rapid determination of antibiotic susceptibilities of bacterial biofilms. J. Clin. Microbiol. 37, 1771-1776 (1999). (Pubitemid 29235221)
20. del Pozo JL, Patel R. The challenge of treating biofilm-Associated bacterial infections. Clin. Pharmacol. Ther. 82, 204-209 (2007). (Pubitemid 47075342)
21. Isiklar ZU, Darouiche RO, Landon GC, Beck T. Efficacy of antibiotics alone for orthopaedic device related infections. Clin. Orthop. Relat. Res. 332, 184-189 (1996). (Pubitemid 26372868)
22. Tsukayama DT, Goldberg VM, Kyle R. Diagnosis and management of infection after total knee arthroplasty. J. Bone Joint Surg. Am. 85-(Suppl. 1), S75-S80 (2003).
23. Ariza J, Euba G, Murillo O. Orthopedic device-related infections. Enferm. Infect. Microbiol. Clin. 26, 380-390 (2008). (Pubitemid 351879849)
24. Hanssen AD, Rand JA. Evaluation and treatment of infection at the site of a total hip or knee arthroplasty. Instr. Course Lect. 48, 111-122 (1999).
25. Tsukayama DT, Estrada R, Gustilo RB. Infection after total hip arthroplasty. A study of the treatment of one hundred and six infections. J. Bone Joint Surg. Am. 78, 512-523 (1996). (Pubitemid 26115571)
26. del Pozo JL, Patel R, Clinical practice. Infection associated with prosthetic joints. N. Engl. J. Med. 361, 787-794 (2009).
27. Tattevin P, Cremieux AC, Pottier P et al. Prosthetic joint infection, when can prosthesis salvage be considered? Clin. Infect. Dis. 29, 292-295 (1999). (Pubitemid 29380187)
28. Atkins BL, Athanasou N, Deeks JJ et al. Prospective evaluation of criteria for microbiological diagnosis of prosthetic-joint infection at revision arthroplasty. The OSIRIS collaborative study group. J. Clin. Microbiol. 36, 2932-2939 (1998). (Pubitemid 28429417)
29. Trampuz A, Widmer AF. Infections associated with orthopedic implants. Curr. Opin. Infect. Dis. 19, 349-356 (2006). (Pubitemid 43982507)
30. Tunney MM, Dunne N, Einarsson G et al. Biofilm formation by bacteria isolated from retrieved failed prosthetic hip implants in an in vitro model of hip arthroplasty antibiotic prophylaxis. J. Orthop. Res. 25, 2-10 (2007). (Pubitemid 46070726)
31. Della VC, Parvizi J, Bauer TW et al. Diagnosis of periprosthetic joint infections of the hip and knee. J. Am. Acad. Orthop. Surg. 18, 760-770 (2010).
32. Athanasou NA, Pandey R, de Steiger R et al. Diagnosis of infection by frozen section during revision arthroplasty. J. Bone Joint Surg. Br. 77, 28-33 (1995).
33. Schinsky MF, la Valle CJ, Sporer SM, Paprosky WG. Perioperative testing for joint infection in patients undergoing revision total hip arthroplasty. J. Bone Joint Surg. Am. 90, 1869-1875 (2008).
34. Spangehl MJ, Masri BA, O'Connell JX, Duncan CP. Prospective analysis of preoperative and intraoperative investigations for the diagnosis of infection at the sites of two hundred and two revision total hip arthroplasties. J. Bone Joint Surg. Am. 81, 672-683 (1999). (Pubitemid 29241152)
35. Pandey R, Berendt AR, Athanasou NA. Histological and microbiological findings in non-infected and infected revision arthroplasty tissues. The OSIRIS collaborative study group. Oxford skeletal infection research and intervention service. Arch. Orthop. Trauma Surg. 120, 570-574 (2000).
36. Trampuz A, Zimmerli W. Antimicrobial agents in orthopaedic surgery, prophylaxis and treatment. Drugs 66, 1089-1105 (2006). (Pubitemid 43945869)
37. Schafer P, Fink B, Sandow D et al. Prolonged bacterial culture to identify late periprosthetic joint infection, a promising strategy. Clin. Infect. Dis. 47, 1403-1409 (2008).
38. Trampuz A, Zimmerli W. Diagnosis and treatment of infections associated with fracture-fixation devices. Injury 37(Suppl. 2), S59-S66 (2006).
39. Trampuz A, Piper KE, Jacobson MJ et al. Sonication of removed hip and knee prostheses for diagnosis of infection. N. Engl. J. Med. 357, 654-663 (2007). (Pubitemid 47267235)
40. Vandercam B, Jeumont S, Cornu O et al. Amplification-based DNA analysis in the diagnosis of prosthetic joint infection. J. Mol. Diagn. 10, 537-543 (2008).
41. Tigges S, Stiles RG, Roberson JR. Complications of hip arthroplasty causing periprosthetic radiolucency on plain radiographs. Am. J. Roentgenol. 162, 1387-1391 (1994). (Pubitemid 24187493)
42. Love C, Tomas MB, Marwin SE et al. Role of nuclear medicine in diagnosis of the infected joint replacement. Radiographics 21, 1229-1238 (2001). (Pubitemid 33707233)
43. Kwee TC, Kwee RM, Alavi A. FDG-PET for diagnosing prosthetic joint infection, systematic review and metaanalysis. Eur. J. Nucl. Med. Mol. Imaging 35, 2122-2132 (2008).
44. Pill SG, Parvizi J, Tang PH et al. Comparison of fluorodeoxyglucose positron emission tomography and (111)indium-white blood cell imaging in the diagnosis of periprosthetic infection of the hip. J. Arthropl. 21, 91-97 (2006). (Pubitemid 44293270)
45. Van Acker F, Nuyts J, Maes A et al. FDG-PET, 99mTc-HMPAO white blood cell SPET and bone scintigraphy in the evaluation of painful total knee arthroplasties. Eur. J. Nucl. Med. 28, 1496-1504 (2001).
46. Pakos EE, Trikalinos TA, Fotopoulos AD, Ioannidis JP. Prosthesis infection, diagnosis after total joint arthroplasty with antigranulocyte scintigraphy with 99mTc-labeled monoclonal antibodies - a metaanalysis. Radiology 242, 101-108 (2007). (Pubitemid 44956014)
47. Zimmerli W. Infection and musculoskeletal conditions. Prosthetic-joint-associated infections. Best Pract. Res. Clin. Rheumatol. 20, 1045-1063 (2006).
48. Zimmerli W, Ochsner PE. Management of infection associated with prosthetic joints. Infection 31, 99-108 (2003). (Pubitemid 36437724)
49. Langlais F, Belot N, Ropars M et al. Antibiotic cements in articular prostheses, current orthopaedic concepts. Int. J. Antimicrob. Agents 28, 84-89 (2006). (Pubitemid 44108604)
50. Betsch BY, Eggli S, Siebenrock KA et al. Treatment of joint prosthesis infection in accordance with current recommendations improves outcome. Clin. Infect. Dis. 46, 1221-1226 (2008). (Pubitemid 351589906)
51. Giulieri SG, Graber P, Ochsner PE, Zimmerli W. Management of infection associated with total hip arthroplasty according to a treatment algorithm. Infection 32, 222-228 (2004). (Pubitemid 39070602)
52. Laffer RR, Graber P, Ochsner PE, Zimmerli W. Outcome of prosthetic knee-asociated infection, evaluation of 40 consecutive episodes at a single centre. Clin. Microbiol. Infect. 12, 433-439 (2006).
53. Vilchez F, Martinez-Pastor JC, Garcia- Ramiro S et al. Outcome and predictors of treatment failure in early post-surgical prosthetic joint infections due to Staphylococcus aureus treated with debridement. Clin. Microbiol. Infect. 17(3), 439-444 (2011).
54. Berdal JE, Skramm I, Mowinckel P et al. Use of rifampicin and ciprofloxacin combination therapy after surgical debridement in the treatment of early manifestation prosthetic joint infections. Clin. Microbiol. Infect. 11, 843-845 (2005). (Pubitemid 41341720)
55. Aboltins CA, Page MA, Buising KL et al. Treatment of staphylococcal prosthetic joint infections with debridement, prosthesis retention and oral rifampicin and fusidic acid. Clin. Microbiol. Infect. 13, 586-591 (2007). (Pubitemid 46730664)
56. Cobo J, Miguel LG, Euba G et al. Early prosthetic joint infection, outcomes with debridement and implant retention followed by antibiotic therapy. Clin. Microbiol. Infect. DOI: 101111/j.1469-0691201003333x (2010) (Epub ahead of print).
57. Mont MA, Waldman B, Banerjee C et al. Multiple irrigation, debridement, and retention of components in infected total knee arthroplasty. J. Arthroplasty 12, 426-433 (1997). (Pubitemid 29023766)
58. Azzam KA, Seeley M, Ghanem E et al. Irrigation and debridement in the management of prosthetic joint infection, traditional indications revisited. J. Arthroplasty 25(7, 1022-1027 (2010).
59. Deirmengian C, Greenbaum J, Lotke PA et al. Limited success with open debridement and retention of components in the treatment of acute Staphylococcus aureus infections after total knee arthroplasty. J. Arthroplasty 18, 22-26 (2003). (Pubitemid 37259661)
60. Bradbury T, Fehring TK, Taunton M et al. The fate of acute methicillin-resistant Staphylococcus aureus periprosthetic knee infections treated by open debridement and retention of components. J. Arthroplasty 24, 101-104 (2009).
61. Bernard L, Hoffmeyer P, Assal M et al. Trends in the treatment of orthopaedic prosthetic infections. J. Antimicrob. Chemother. 53, 127-129 (2004).
62. Crockarell JR, Hanssen AD, Osmon DR, Morrey BF. Treatment of infection with debridement and retention of the components following hip arthroplasty. J. Bone Joint Surg. Am. 80, 1306-1313 (1998). (Pubitemid 28443354)
63. Soriano A, Garcia S, Bori G et al. Treatment of acute post-surgical infection of joint arthroplasty. Clin. Microbiol. Infect. 12, 930-933 (2006). (Pubitemid 44151298)
64. Rodriguez D, Pigrau C, Euba G et al. Acute hematogenous prosthetic joint infection, prospective evaluation of medical and surgical management. Clin. Microbiol. Infect. DOI: 101111/j.1469-0691200903157x (2009) (Epub ahead of print).
65. Hirakawa K, Stulberg BN, Wilde AH et al. Results of 2-stage reimplantation for infected total knee arthroplasty. J. Arthroplasty 13, 22-28 (1998). (Pubitemid 28082632)
66. Bejon P, Berendt A, Atkins BL et al. Two-stage revision for prosthetic joint infection, predictors of outcome and the role of reimplantation microbiology. J. Antimicrob. Chemother. 65, 569-575 (2010).
67. Barrack RL, McClure JT, Burak CF et al. Revision total knee arthroplasty, the patient's perspective. Clin. Orthop. Relat. Res. 464, 146-150 (2007). (Pubitemid 350059960)
68. Salgado CD, Dash S, Cantey JR, Marculescu CE. Higher risk of failure of methicillin-resistant Staphylococcus aureus prosthetic joint infections. Clin. Orthop. Relat. Res. 461, 48-53 (2007). (Pubitemid 47344093)
69. El Helou OC, Berbari EF, Lahr BD et al. Efficacy and safety of rifampin containing regimen for staphylococcal prosthetic joint infections treated with debridement and retention. Eur. J. Clin. Microbiol. Infect. Dis. 29, 961-967 (2010).
70. Dixon P, Parish EN, Cross MJ. Arthroscopic debridement in the treatment of the infected total knee replacement. J. Bone Joint Surg. Br. 86, 39-42 (2004). (Pubitemid 38128703)
71. Waldman BJ, Hostin E, Mont MA, Hungerford DS. Infected total knee arthroplasty treated by arthroscopic irrigation and debridement. J. Arthroplasty 15, 430-436 (2000). (Pubitemid 30413882)
72. Byren I, Bejon P, Atkins BL et al. One hundred and twelve infected arthroplasties treated with 'DAIR' (debridement, antibiotics and implant retention), antibiotic duration and outcome. J. Antimicrob. Chemother. 63, 1264-1271 (2009).
73. Pavoni GL, Giannella M, Falcone M et al. Conservative medical therapy of prosthetic joint infections, retrospective analysis of an 8 year experience. Clin. Microbiol. Infect. 10, 831-837 (2004). (Pubitemid 39276318)
74. Burnett RS, Kelly MA, Hanssen AD, Barrack RL. Technique and timing of two-stage exchange for infection in TKA. Clin. Orthop. Relat. Res. 464, 164-178 (2007). (Pubitemid 350059963)
75. von Foerster G, Kluber D, Kabler U. Mid- to long-term results after treatment of 118 cases of periprosthetic infections after knee joint replacement using one-stage exchange surgery. Orthopade 20, 244-252 (1991).
76. Jamsen E, Stogiannidis I, Malmivaara A et al. Outcome of prosthesis exchange for infected knee arthroplasty, the effect of treatment approach. Acta. Orthop. 80, 67-77 (2009).
77. Langlais F. Can we improve the results of revision arthroplasty for infected total hip replacement? J. Bone Joint Surg. Br. 85, 637-640 (2003). (Pubitemid 36927023)
78. Bargiotas K, Wohlrab D, Sewecke JJ et al. Arthrodesis of the knee with a long intramedullary nail following the failure of a total knee arthroplasty as the result of infection. Surgical technique. J. Bone Joint Surg. Am. 89(Suppl. 2) Pt 1, 103-110 (2007).
79. Zimmerli W, Widmer AF, Blatter M et al. Role of rifampin for treatment of orthopedic implant-related staphylococcal infections, a randomized controlled trial. Foreign-Body Infection (FBI) study group. JAMA 279, 1537-1541 (1998). (Pubitemid 28233008)
80. Bernard L, Legout L, Zurcher-Pfund L et al. Six weeks of antibiotic treatment is sufficient following surgery for septic arthroplasty. J. Infect. 61, 125-132 (2010).
81. Barberan J, Aguilar L, Carroquino G et al. Conservative treatment of staphylococcal prosthetic joint infections in elderly patients. Am. J. Med. 119(11), 993 e7-e10 (2006).
82. Piso RJ, Elke R. Antibiotic treatment can be safely stopped in asymptomatic patients with prosthetic joint infections despite persistent elevated C-reactive protein values. Infection 38, 293-296 (2010).
83. Widmer AF, Wiestner A, Frei R, Zimmerli W. Killing of nongrowing and adherent Escherichia coli determines drug efficacy in device-related infections. Antimicrob. Agents Chemother. 35, 741-746 (1991).
84. Zimmerli W, Frei R, Widmer AF, Rajacic Z. Microbiological tests to predict treatment outcome in experimental device-related infections due to Staphylococcus aureus. J. Antimicrob. Chemother. 33, 959-967 (1994). (Pubitemid 24170895)
85. Blaser J, Vergeres P, Widmer AF, Zimmerli W. In vivo verification of in vitro model of antibiotic treatment of device-related infection. Antimicrob. Agents Chemother. 39, 1134-1139 (1995).
86. Widmer AF, Gaechter A, Ochsner PE, Zimmerli W. Antimicrobial treatment of orthopedic implant-related infections with rifampin combinations. Clin. Infect. Dis. 14, 1251-1253 (1992).
87. Chuard C, Herrmann M, Vaudaux P et al. Successful therapy of experimental chronic foreign-body infection due to methicillin-resistant Staphylococcus aureus by antimicrobial combinations. Antimicrob. Agents Chemother. 35, 2611-2616 (1991).
88. Kang SL, Rybak MJ, McGrath BJ et al. Pharmacodynamics of levofloxacin, ofloxacin, and ciprofloxacin, alone and in combination with rifampin, against methicillin-susceptible and -resistant Staphylococcus aureus in an in vitro infection model. Antimicrob. Agents Chemother. 38, 2702-2709 (1994). (Pubitemid 24374424)
89. Murillo O, Domenech A, Garcia A et al. Efficacy of high doses of levofloxacin in experimental foreign-body infection by methicillin-susceptible Staphylococcus aureus. Antimicrob. Agents Chemother. 50, 4011-4017 (2006). (Pubitemid 44865143)
90. Senneville E, Poissy J, Legout L et al. Safety of prolonged high-dose levofloxacin therapy for bone infections. J. Chemother. 19, 688-693 (2007). (Pubitemid 351212019)
91. Lovering AM, Zhang J, Bannister GC et al. Penetration of linezolid into bone, fat, muscle and haematoma of patients undergoing routine hip replacement. J. Antimicrob. Chemother. 50, 73-77 (2002). (Pubitemid 34785257)
92. Murillo O, Domenech A, Euba G et al. Efficacy of linezolid alone and in combination with rifampin in staphylococcal experimental foreign-body infection. J. Infect. 57, 229-235 (2008).
93. Baldoni D, Haschke M, Rajacic Z et al. Linezolid alone or combined with rifampin against methicillin-resistant Staphylococcus aureus in experimental foreign-body infection. Antimicrob. Agents. Chemother. 53, 1142-1148 (2009).
94. Aneziokoro CO, Cannon JP, Pachucki CT, Lentino JR. The effectiveness and safety of oral linezolid for the primary and secondary treatment of osteomyelitis. J. Chemother. 17, 643-650 (2005). (Pubitemid 43097752)
95. Bassetti M, Righi E, Di Biagio A et al. Role of linezolid in the treatment of orthopedic infections. Expert. Rev. Anti. Infect. Ther. 3, 343-352 (2005). (Pubitemid 40872529)
96. Falagas ME, Siempos II, Papagelopoulos PJ, Vardakas KZ. Linezolid for the treatment of adults with bone and joint infections. Int. J. Antimicrob. Agents 29, 233-239 (2007). (Pubitemid 46240739)
97. Rao N, Hamilton CW. Efficacy and safety of linezolid for Gram-positive orthopedic infections, a prospective case series. Diagn. Microbiol. Infect. Dis. 59, 173-179 (2007). (Pubitemid 47484126)
98. Soriano A, Gomez J, Gomez L et al. Efficacy and tolerability of prolonged linezolid therapy in the treatment of orthopedic implant infections. Eur. J. Clin. Microbiol. Infect. Dis. 26, 353-356 (2007). (Pubitemid 46716796)
99. Plachouras D, Giannitsioti E, Athanassia S et al. No effect of pyridoxine on the incidence of myelosuppression during prolonged linezolid treatment. Clin. Infect. Dis. 43, e89-e91 (2006).
100. Rucker JC, Hamilton SR, Bardenstein D et al. Linezolid-associated toxic optic neuropathy. Neurology 66, 595-598 (2006).
101. Mascio CT, Alder JD, Silverman JA. Bactericidal action of daptomycin against stationary-phase and nondividing Staphylococcus aureus cells. Antimicrob. Agents Chemother. 51, 4255-4260 (2007). (Pubitemid 350209874)
102. Falagas ME, Giannopoulou KP, Ntziora F, Papagelopoulos PJ. Daptomycin for treatment of patients with bone and joint infections, a systematic review of the clinical evidence. Int. J. Antimicrob. Agents 30, 202-209 (2007). (Pubitemid 47126811)
103. Stein A, Bataille JF, Drancourt M et al. Ambulatory treatment of multidrug-resistant staphylococcus-infected orthopedic implants with high-dose oral co-trimoxazole (trimethoprim-sulfamethoxazole).Antimicrob. Agents Chemother. 42, 3086-3091 (1998). (Pubitemid 28553722)
104. Euba G, Murillo O, Fernandez-Sabe N et al. Long-term follow-up trial of oral rifampin-cotrimoxazole combination versus intravenous cloxacillin in treatment of chronic staphylococcal osteomyelitis. Antimicrob. Agents Chemother. 53, 2672-2676 (2009).
105. Drancourt M, Stein A, Argenson JN et al. Oral treatment of Staphylococcus spp. infected orthopaedic implants with fusidic acid or ofloxacin in combination with rifampicin. J. Antimicrob. Chemother. 39, 235-240 (1997). (Pubitemid 27116419)
106. Rao N, Crossett LS, Sinha RK, Le Frock JL. Long-term suppression of infection in total joint arthroplasty. Clin. Orthop. Relat. Res. 414, 55-60 (2003). (Pubitemid 37102135)
107. Segreti J, Nelson JA, Trenholme GM. Prolonged suppressive antibiotic therapy for infected orthopedic prostheses. Clin. Infect. Dis. 27, 711-713 (1998). (Pubitemid 29244322)
108. Tsukayama DT, Wicklund B, Gustilo RB. Suppressive antibiotic therapy in chronic prosthetic joint infections. Orthopedics 14, 841-844 (1991).
109. Marculescu CE, Berbari EF, Hanssen AD et al. Outcome of prosthetic joint infections treated with debridement and retention of components. Clin. Infect. Dis. 42, 471-478 (2006). (Pubitemid 43202518)
110. van der Linden PD, Sturkenboom MC, Herings RM et al. Increased risk of achilles tendon rupture with quinolone antibacterial use, especially in elderly patients taking oral corticosteroids. Arch. Intern. Med. 163, 1801-1807 (2003). (Pubitemid 36960927)
111. Whittaker JP, Warren RE, Jones RS, Gregson PA. Is prolonged systemic antibiotic treatment essential in two-stage revision hip replacement for chronic Gram-positive infection? J. Bone Joint Surg. Br. 91, 44-51 (2009).
112. Hoad-Reddick DA, Evans CR, Norman P, Stockley I. Is there a role for extended antibiotic therapy in a two-stage revision of the infected knee arthroplasty? J. Bone Joint Surg. Br. 87, 171-174 (2005). (Pubitemid 40278014)
113. Stockley I, Mockford BJ, Hoad-Reddick A, Norman P. The use of two-stage exchange arthroplasty with depot antibiotics in the absence of long-term antibiotic therapy in infected total hip replacement. J. Bone Joint Surg. Br. 90, 145-148 (2008). (Pubitemid 351303337)
114. McKenna PB, O'Shea K, Masterson EL. Two-stage revision of infected hip arthroplasty using a shortened post-operative course of antibiotics. Arch. Orthop. Trauma Surg. 129, 489-494 (2009).
115. Mont MA, Waldman BJ, Hungerford DS. Evaluation of preoperative cultures before second-stage reimplantation of a total knee prosthesis complicated by infection. A comparison-group study. J. Bone Joint Surg. Am. 82-a, 1552-1557 (2000).
116. Ghanem E, Azzam K, Seeley M et al. Staged revision for knee arthroplasty infection, what is the role of serologic tests before reimplantation? Clin. Orthop. Relat. Res. 467, 1699-1705 (2009).
117. Lonner JH, Siliski JM, Della VC et al. Role of knee aspiration after resection of the infected total knee arthroplasty. Am. J. Orthop (Belle Mead NJ) 30, 305-309 (2001).
118. Kendall RW, Duncan CP, Smith JA, Ngui-Yen JH. Persistence of bacteria on antibiotic loaded acrylic depots. A reason for caution. Clin. Orthop. Relat. Res. 273-280 (1996). (Pubitemid 26274681)
119. Murillo O, Euba G, Calatayud L et al. The role of intraoperative cultures at the time of reimplantation in the management of infected total joint arthroplasty. Eur. J. Clin. Microbiol. Infect. Dis. 27, 805-811 (2008).
120. Anagnostakos K, Hitzler P, Pape D et al. Persistence of bacterial growth on antibiotic-loaded beads, is it actually a problem? Acta. Orthop. 79, 302-307 (2008). (Pubitemid 351878362)